Cost Effectiveness of Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement.
Pharmacoeconomic Evaluation
Commenced | Completed | Outcome |
May 2008 | September 2008 | Reimbursement recommended. |
A summary of the main findings are included in the attached document.